Scotiabank analyst Greg Harrison initiated coverage of Arcturus Therapeutics (ARCT) with an Outperform rating and $32 price target The shares are trading near the company’s cash position “with plenty of upside potential in the therapeutics pipeline,” the analyst tells investors in a research note. The firm believes Arcturus shares are “significantly undervalued” given the potential of the company’s therapeutics pipeline in cystic fibrosis and ornithine transcarbamylase deficiency.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Arcturus Therapeutics: Earnings Call Highlights Progress and Challenges
- Arcturus Therapeutics price target lowered to $45 from $50 at Wells Fargo
- Arcturus Therapeutics: Strategic Focus and Promising CF Program Drive Buy Rating
- Promising Developments and Strategic Financial Management Drive Buy Rating for Arcturus Therapeutics
- Arcturus Therapeutics price target lowered to $66 from $68 at Canaccord